BTT+CAP Slaughter Flashcards
Survival?
180d = 91%
360d = 84%
N=?
Primary Outcome?
N=332. (140+192)
Success=Survival on orig. device, transplant or explant for recovery
Conclusion ?
HVAD as BTT demonstrates high 180d survival rate despite low transplant rate.
AE’s are similar or better than historical BTT trials, despite longer exposure times due to longer survival & lower transplant rates.
Follow up ?
At least 6 mos. to
Over 3 years
Analysis July 31, 2012
Driveline Infection
- 9% 56/332
0. 25 PPY
Bleeding
Req. Surgery 14.8% 49/332
0.19 PPY
GI Bleeding 12.7% 42/332
0.28 PPY
Stroke Overall
- 8% (2pts having both)
28. 6% of stroke events fatal
ICVA
- 5% 25/332
- 09 PPY
88% survived event
HCVA
- 8% 26/332
- 09 PPY
46% of HCVA’s fatal
Hemolysis
- 2% 4/332
0. 02 PPY
Thrombus
Device Exchange
4.2%
- 7%
- 2.1% proc. related
- 4.2% suspected thrombus
- 2.4% other
After March 15, 2011 Pump Exchange for Thrombus
0.063 PPY to 0.027 PPY
55% drop
After March 15, 2011 Strokes
ICVA w/ MRS>0
5.1% to 2.8% (45% drop)
0.089 PPY to 0.047 PPY
HCVA’s w/MRS >0
5.1% to 4.7% (8% drop)
0.082 PPY to 0.074 PPY
6MWT distance improvement
Distance tripled
Study duration
3 yrs. 4 mos
August 2008 - December 2011
Medical Therapy & Device Design Enhancements March 2011 - December 2011